Abstract
India’s pharmaceutical industry is of considerable economic importance—as one of India’s largest manufacturing industries and a major contributor of exports. Yet, it is perhaps of most significance for health—as a major supplier of generic medicines, for which it is sometimes known as the “pharmacy of the world”. The sector faces a number of challenges in order to ensure greater societal benefit from the industry in India. Some of the major issues relate to production in terms of quality and environmental impact, to research in terms of appropriate patent laws and regulating clinical trials, and also to marketing related to prices and access to medicines. Yet the sector, with its distinctive character of consumption and significance for public health, is one where little substantive momentum has emerged around voluntary governance initiatives. Widespread agreement exists on the need for more effective public regulation to maximise the societal benefits of the industry.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
Estimates for the number of firms in India’s pharmaceutical industry vary considerably.
- 2.
A Pharmacopoeia is “an official (legally binding) publication containing recommended quality specifications for the analysis and determinations of drug substances, specific dosage forms, excipients and finished drug products” (Rägo and Santoso 2008, 72).
- 3.
MCA uploaded the new guidelines for public comments in June 2018. http://www.mca.gov.in/Ministry/pdf/DraftNationalGuidelines2018_20062018.pdf.
References
Bartley, Tim. 2007. Institutional Emergence in an Era of Globalization: The Rise of Transnational Private Regulation of Labor and Environmental Conditions. American Journal of Sociology 113 (2): 297–351.
———. 2018. Rules Without Rights: Land, Labor and Private Authority in the Global Economy. Oxford: Oxford University Press.
Batham, Vikash, Rijit Sengupta, and Vasanthi Srinivasan. 2013. Rethinking Business Responsibility in India: A Review of Pharmaceutical & Private Healthcare Sectors. Jaipur: CUTS International.
Bermudez, Jorge, and Ellen t’Hoen. 2010. The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good. The Open AIDS Journal 4: 37–40.
Bloomfield, Michael, and Philip Schleifer. 2017. Tracing Failure of Coral Reef Protection in Non-state Market-driven Governance. Global Environmental Politics 17 (4): 127–146.
Brhlikova, Petra, Ian Harper, Roger Jeffery, Nabin Rawal, Madhusudhan Subedi, and M.R. Santhosh. 2011. Trust and the Regulation of Pharmaceuticals: South Asia in a Globalised World. Globalization and Health 7 (1): 1–13.
Business Standard. 2015. Govt to Create Separate Ministry for Pharma in One Year: Ananth Kumar. Business Standard, December 10. Accessed August 1, 2017. http://www.business-standard.com/article/economy-policy/govt-to-create-separate-ministry-for-pharma-in-one-year-ananth-kumar-115120901043_1.html.
Chatterjee, Partha. 2010. The State. In The Oxford Companion to Politics in India, ed. Niraja Gopal-Jayal and Pratap Bhanu Mehta, 3–14. New Delhi: Oxford University Press.
Chaturvedi, Umesh, Monica Sharma, G.S. Dangayach, and Prabir Sarkar. 2017. Evolution and Adoption of Sustainable Practices in the Pharmaceutical Industry: An Overview with an Indian Perspective. Journal of Cleaner Production 168: 1358–1369.
Chaudhuri, Sudip. 2005. The WTO and India’s Pharmaceutical Industry: Patent Protection, TRIPs and Developing Countries. New Delhi: Oxford University Press.
———. 2007. The Gap Between Successful Innovation and Access to its Benefits: Indian Pharmaceuticals. The European Journal of Development Research 19 (1): 49–65.
———. 2013. The Larger Implications of the Novartis-Glivec Judgement. Economic and Political Weekly XLVIII (17): 10–12.
Cipla. 2015. CIPLA Business Responsibility Report 2014–15. Mumbai: Cipla. Accessed July 24, 2017. http://www.cipla.com/uploads/investor/1444633276_Business_Responsibility_Report_2014_15.pdf.
CUTS. 2014. National Voluntary Guidelines on Social, Environmental and Economic Responsibilities for the Pharmaceutical Sector. Consumer Unity and Trust Society. http://www.cuts-ccier.org/BRGP/pdf/National_Voluntary_Guidelines_for_Pharmaceutical_Sector.pdf
D’Mello, Bernard. 2002. Transnational Pharmaceutical Corporations and Neo-liberal Business Ethics in India. Journal of Business Ethics 36 (1): 165–185.
Das, Keshab. 2003. The Domestic Politics of TRIPs: Pharmaceutical Interests, Public Health and NGO Influence in India. Ahmedabad: Gujarat Institute of Development Research. https://pdfs.semanticscholar.org/3288/5e3759af97348c1e4b5204a69943749e1d30.pdf.
Department of Pharmaceuticals. 2015. Recommendations of the Task Force on Enabling Private Sector to Lead the Growth of Pharmaceutical Industry. New Delhi: Government of India.
———. 2017. Annual Report 2016–17. New Delhi: Department of Pharmaceuticals, Government of India.
———. 2018. Janaushadhi Scheme. Accessed June 6, 2018. http://pharmaceuticals.gov.in/schemes/janaushadhi-scheme.
Drahos, Peter, with John Braithwaite. 2002. Information Feudalism: Who Owns the Knowledge Economy? New Delhi: Oxford University Press.
Earth Security Group. 2017. The Earth Security Report 2017: Sustainable Development Goals for Business Diplomacy and Growth. https://earthsecuritygroup.com/strategy-briefs/earth-security-report-2017.
Export–Import Bank of India. 2016. Indian Pharmaceutical Industry: Challenges and Prospects. Occasional Paper No. 176, New Delhi, Government of India.
FICCI. 2015. Realising “Make in India”—Journey to Become the Most Preferred Manufacturer of High Quality Affordable Medicines. New Delhi: FICCI.
Fransen, Luc, and Thomas Conzelmann. 2015. Fragmented or Cohesive Transnational Private Regulation of Sustainability Standards? A Comparative Study. Regulation & Governance 9 (3): 259–275.
Ghosh, Soumitra. 2011. Catastrophic Payments and Impoverishment Due to Out-of-Pocket Health Spending. Economic and Political Weekly 46 (47): 63–70.
Giovannucci, Daniele, and Stefano Ponte. 2005. Standards as a New Form of Social Contract? Sustainability Initiatives in the Coffee Industry. Food Policy 30 (3): 284–301.
GIZ, Global Reporting Initiative and Thought Arbitrage Research Institute. 2012. Sustainability Reporting: Practices and Trends in India 2012. New Delhi: GIZ.
Gothoskar, S.S. 1983. Drug Control: India. World Development 11 (3): 223–228.
Government of India. 1961. Report of the Health Survey and Planning Committee. New Delhi: Ministry of Health.
———. 1975. Report of the Committee on Drugs and Pharmaceutical Industry. Hathi Committee Report. New Delhi: Ministry of Petroleum and Chemicals.
———. 2003. Report of the Expert Committee on a Comprehensive Examination of Drug Regulatory Issues, Including the Problem of Spurious Drugs. New Delhi: Ministry of Health and Family Welfare.
———. 2005. Report of the National Commission on Macroeconomics and Health. New Delhi: Ministry of Health and Family Welfare, Government of India.
———. 2012. Fifty-Ninth Report on the Functioning of the Central Drugs Standard Control Organisation (CDSCO) (Committee on Health and Family Welfare). New Delhi: Rajya Sabha Secretariat.
Grande, David. 2010. Limiting the Influence of Pharmaceutical Industry Gifts on Physicians: Self-Regulation or Government Intervention? Journal of General Internal Medicine 25 (1): 79–83.
Gray, Andy. 2004. Access to Medicines and Drug Regulation in Developing Countries: A Resource Guide for DFID. London: DFID Health Systems Resource Centre.
Haakonsson, Stine. 2009. The Changing Governance Structures of the Global Pharmaceutical Value Chain. Competition & Change 13 (1): 75–95.
Hamied, Yusuf. 1988. The Indian Patents Act 1970 and the Pharmaceutical Industry. In Conquest by Patent: On Patent Law and Policy, ed. Nitya Nand, Chap. 15. New Delhi: National Working Group on Patent Laws.
Horner, Rory. 2013. The Global Relevance of India’s Pharmaceutical Patent Laws. Economic and Political Weekly XLVIII (31): 16–18.
———. 2014a. Strategic Decoupling, Recoupling and Global Production Networks: India’s Pharmaceutical Industry. Journal of Economic Geography 14 (6): 1117–1140.
———. 2014b. The Impact of Patents on Innovation, Technology Transfer and Health: A Pre- and Post-TRIPs Analysis of India’s Pharmaceutical Industry. New Political Economy 19 (3): 384–406.
———. 2016. Pharmaceuticals and the Global South: A Healthy Challenge for Development Theory? Geography Compass 10 (9): 363–377.
Horner, Rory, and James T. Murphy. 2018. South–North and South–South Production Networks: Diverging Socio-spatial Practices of Indian Pharmaceutical Firms. Global Networks 18 (2): 326–351.
ITC. 2017. The State of Sustainable Markets. Geneva: International Trade Center.
Jose, P.D., and Saurabh Saraf. 2013. Corporate Sustainability Initiative’s Reporting: A Study of India’s Most Valuable Companies. IIM Bangalore Research Paper No. 428. Available at SSRN: https://ssrn.com/abstract=2352776 or https://doi.org/10.2139/ssrn.2352776.
Joseph, Reji. 2015. Pharmaceutical Industry and Public Policy in Post-reform India. New Delhi: Routledge.
Kochanek, Stanley. 1974. Business and Politics in India. Los Angeles, CA: University of California Press.
Lal, Harivan. 1990. Drugs Industry, Social Responsibility and the Multinationals. New Delhi: Commonwealth Publishers.
Larsson, D.G. Joakim, Cecelia de Pedro, and Nicklas Paxeus. 2007. Effluent from Drug Manufactures Contains Extremely High Levels of Pharmaceuticals. Journal of Hazardous Materials 148: 751–755.
Maenen, Seth, and Axel Marx. 2012. From Multi-stakeholder Dialogue to Certification Initiative. What Drives the Emergence of Certification Initiatives? In ECPR Conference, Exeter, June 27–29.
Maiti, Rituparna, Vikas Bhatia, Biswa Mohan Padhy, and Debasish Hota. 2015. Essential Medicines: An Indian Perspective. Indian Journal of Community Medicine: Official Publication of Indian Association of Preventive & Social Medicine 40 (4): 223.
Mayer, Frederick, and Gary Gereffi. 2010. Regulation and Economic Globalization: Prospects and Limits of Private Governance. Business and Politics 12 (3): 1–25.
Mondal, Swadhin, and Dinesh Abrol. 2015. Clinical Trials Industry in India: A Systematic Review. New Delhi: Institute for Studies in Industrial Development.
Moon, Surie. 2008. Medicines as Global Public Goods: The Governance of Technological Innovation in the New Era of Global Health. Global Health Governance II (2): 1–23.
MSF. 2007. Examples of the Importance of India as the “Pharmacy of the Developing World”. Medecins Sans Frontieres. Accessed July 27, 2017. http://www.msfaccess.org/sites/default/files/MSF_assets/Access/Docs/ACCESS_briefing_Pharmacy-ForDevelopingWorld_India_ENG_2007.pdf.
Nadvi, Khalid. 2014. “Rising Powers” and Labour and Environmental Standards. Oxford Development Studies 42 (2): 137–150.
National Pharmaceutical Pricing Authority (NPPA). 2007. Directory of Pharmaceutical Manufacturing Units in India. New Delhi: Government of India.
Nordea. 2016. Impacts of Pharmaceutical Pollution on Communities and Environment in India. Nordea Asset Management. Accessed August 4, 2017. https://www.nordea.com/Images/35-107206/impacts%201-20.pdf.
Patnaik, Jagadish K. 1992. India and the TRIPs: Some Notes on the Uruguay Round of Negotiations. India Quarterly 48 (4): 31–42.
Potts, Jason, Matthew Lynch, Ann Wilkings, Gabriel Huppé, Maxine Cunningham, and Vivek Voora. 2014. The State of Sustainability Initiatives Review 2014: Standards and the Green Economy. Winnipeg and London; International Institute for Sustainable Development (IISD) and International Institute for Environment and Development (IIED).
Rägo, Lembit, and Budiono Santoso. 2008. Drug Regulation: History, Present and Future. In Drug Benefits and Risks: International Textbook of Clinical Pharmacology, ed. Chris J. van Boxtel, Budiono Santoso, and I. Ralph Edwards, 65–77. Amsterdam: IOS Press and Uppsala Monitoring Centre.
Roemer-Mahler, Anne. 2013. Business Conflict and Global Politics: The Pharmaceutical Industry and the Global Protection of Intellectual Property Rights. Review of International Political Economy 20 (1): 121–152.
Sangar, Shivendra, Varun Dutt, and Ramna Thakur. 2018. Economic Burden, Impoverishment and Coping Mechanisms Associated with Out-of-pocket Health Expenditure: Analysis of Rural-Urban Differentials in India. Journal of Public Health: 1–10. https://doi.org/10.1002/hpm.2649.
Sariola, Salla, Deapica Ravindran, Anand Kumar, and Roger Jeffery. 2015. Big-pharmaceuticalisation: Clinical Trials and Contract Research Organisations in India. Social Science & Medicine 131: 239–246.
Selvaraj, Sakthivel, et al. 2012. Pharmaceutical Pricing Policy: A Critique. Economic and Political Weekly 47 (4): 20–23.
Shukla, Abhay, and Anant Phadke. 1999. Health Movement in India. Health Action 12 (12): 6–9.
Sood, Atul, and Bimal Arora. 2006. The Political Economy of Corporate Social Responsibility in India. Geneva: United Nations Research Institute for Social Development.
Srinivasan, S. 2011. ‘Medicines for All’, the Pharma Industry and the Indian State. Economic and Political Weekly XLVI (24): 43–50.
Sweet, Cassandra, and Keshab Das. 2010. Institutional and Procedural Challenges to Generic Production in India: Antiretrovirals in Focus. Ahmedabad: Gujarat Institute of Development Research.
The Economic Times. 2017. No More Freebies: Modi Government Plans Crackdown on Marketing by Drugmakers. The Economic Times, August 3, 2017. http://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/no-more-freebies-modi-government-plans-crackdown-on-marketing-by-drugmakers/articleshow/59880497.cms
Töller, Annette Elisabeth. 2017. Voluntary Regulation by the Pharmaceutical Industry—Which Role for the Shadow of Hierarchy and Social Pressure? European Policy Analysis 3 (1): 48–80.
U.S. Senate. 1961. Administered Prices: Drugs. Report of the Committee on the Judiciary, U.S. Senate, made by the Subcommittee on Antitrust and Monopoly, 87th Congress, 1st Session, Report No. 448. Washington, DC: Government Printing Office.
Vogel, David. 2008. Global Private Business Regulation. Annual Review of Political Science 11: 261–282.
WHO. 2003. Effective Medicines Regulation: Ensuring Safety, Efficacy and Quality. Geneva: World Health Organization.
———. 2015. Health in 2015: From MDGs to SDGs. Geneva: World Health Organization.
Working Group on Drugs and Pharmaceuticals. 2011. Report of the Working Group on Drugs & Pharmaceuticals for the 12th Five Year Plan. New Delhi: Planning Commission, Government of India.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 The Author(s)
About this chapter
Cite this chapter
Horner, R. (2019). India’s Pharmaceutical Industry and the Enduring Public Regulation Challenge. In: Arora, B., Budhwar, P., Jyoti, D. (eds) Business Responsibility and Sustainability in India. Palgrave Studies in Indian Management. Palgrave Macmillan, Cham. https://doi.org/10.1007/978-3-030-13716-8_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-13716-8_11
Published:
Publisher Name: Palgrave Macmillan, Cham
Print ISBN: 978-3-030-13715-1
Online ISBN: 978-3-030-13716-8
eBook Packages: Business and ManagementBusiness and Management (R0)